Lung Cancer
Non-Small Cell Lung Cancer II
Early-Stage Lung Cancer: Assessment and Treatment
Lung Cancer: Assessment and Treatment
Adjuvant durvalumab does not extend DFS in early-stage lung cancer
Adjuvant durvalumab failed to improve outcomes compared with placebo for certain patients with early-stage lung cancer, according to the agent’s manufacturer.
Q&A: Initiative aims to help more Maryland residents get screened for lung cancer
The risk for lung cancer has been found to be particularly high in some Maryland counties, but a recently launched initiative is making sure screening is available for all eligible state residents, according to a press release.
Money, marketing and inclusion needed to ‘eradicate that gap’ in health care disparities
Robert A. Winn, MD, FAACR, first called for celebration.
Risk for lung cancer reoccurrence may be associated with OSA-related hypoxemia
Potential risk factors for lung cancer reoccurrence within 2 years include obstructive sleep apnea-related episodic hypoxemia and hypoxic burden, according to research presented at SLEEP 2024.
Clinic designed to minimize autoimmune effects of immunotherapy treatment
A new clinic at The Ohio State University — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and Pelotonia Institute for Immuno-Oncology seeks to minimize the autoimmune effects of immunotherapy cancer treatment.
Air pollution linked to heart disease, cancer risk, likely via shared risk factors
Air pollution exposure may contribute to both CV and cancer risk by interacting with various common risk factors such as inflammation, oxidative stress and epigenetic modifications, according to a state-of-the-art review.
Positive results in lung cancer show benefits of subcutaneous bispecifics
CHICAGO — The addition of subcutaneous amivantamab to lazertinib demonstrated noninferior pharmacokinetics and objective response rate compared with intravenous amivantamab, results from a phase 3 study showed.